Application of Targeted Therapy to Malignant Gliomas and Response to Treatment

被引：0

作者：

Lee, Eudocia Q. ^{[1
,2
]}

Norden, Andrew D. ^{[1
,2
]}

Drappatz, Jan ^{[3
]}

Wen, Patrick Y. ^{[1
,2
]}

机构：

[1] Brigham & Womens Hosp, Dept Neurol, Div Canc Neurol, Ctr Neurooncol,Dana Farber Brigham & Womens Canc, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Cambridge, MA 02138 USA

[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

来源：

CURRENT SIGNAL TRANSDUCTION THERAPY | 2013年 / 8卷 / 01期

关键词：

Targeted therapy; malignant glioma; angiogenesis; clinical trials; multi-targeted therapy; PHASE-II TRIAL; GROWTH-FACTOR-RECEPTOR; RECURRENT GLIOBLASTOMA-MULTIFORME; HIGH-GRADE GLIOMAS; BEVACIZUMAB PLUS IRINOTECAN; NEWLY-DIAGNOSED GLIOBLASTOMA; PROGRESSION-FREE SURVIVAL; BRAIN-TUMOR CONSORTIUM; SCATTER FACTOR EXPRESSION; CANCER STEM-CELLS;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The prognosis for malignant gliomas remains poor despite multimodality therapy. An increased understanding of the molecular pathogenesis involved in glioma development and growth has resulted in development of agents that specifically target these molecular processes and pathways. Except for inhibitors of the vascular endothelial growth factor pathway, results from most single agent trials have been modest at best. Tailoring therapy to the individual patients is an attractive strategy although most studies have failed to determine predictive biomarkers. Numerous novel agents, multi-targeted agents, and combination therapies are now in clinical trials for malignant glioma.

引用

页码：14 / 24

页数：11

共 138 条

[1]

Adams J, 1999, CANCER RES, V59, P2615

[2] EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN ASTROCYTIC TUMORS IS SPECIFICALLY ASSOCIATED WITH GLIOBLASTOMA-MULTIFORME [J].

AGOSTI, RM ;

LEUTHOLD, M ;

GULLICK, WJ ;

YASARGIL, MG ;

WIESTLER, OD .

VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1992, 420 (04) :321-325

[3] Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance [J].

Aldape, KD ;

Ballman, K ;

Furth, A ;

Buckner, JC ;

Giannini, C ;

Burger, PC ;

Scheithauer, BW ;

Jenkins, RB ;

James, CD .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2004, 63 (07) :700-707

[4] Exploitation of protein kinase C: A useful target for cancer therapy [J].

Ali, Ashhar S. ;

Ali, Shadan ;

El-Rayes, Basset F. ;

Philip, Philip A. ;

Sarkar, Fazlul H. .

CANCER TREATMENT REVIEWS, 2009, 35 (01) :1-8

[5]

An WG, 2000, CELL GROWTH DIFFER, V11, P355

[6]

[Anonymous], STAT REP PRIM BRAIN

[7] The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme [J].

Ballman, Karla V. ;

Buckner, Jan C. ;

Brown, Paul D. ;

Giannini, Caterina ;

Flynn, Patrick J. ;

LaPlant, Betsy R. ;

Jaeckle, Kurt A. .

NEURO-ONCOLOGY, 2007, 9 (01) :29-38

[8] Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor [J].

Bao, Shideng ;

Wu, Qiulian ;

Sathornsumetee, Sith ;

Hao, Yueling ;

Li, Zhizhong ;

Hjelmeland, Anita B. ;

Shi, Oing ;

McLendon, Roger E. ;

Bigner, Darell D. ;

Rich, Jeremy N. .

CANCER RESEARCH, 2006, 66 (16) :7843-7848

[9] Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function [J].

Basso, AD ;

Solit, DB ;

Chiosis, G ;

Giri, B ;

Tsichlis, P ;

Rosen, N .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :39858-39866

[10] Mutation analysis of B-RAF gene in human gliomas [J].

Basto, D ;

Trovisco, V ;

Lopes, JM ;

Martins, A ;

Pardal, F ;

Soares, P ;

Reis, RM .

ACTA NEUROPATHOLOGICA, 2005, 109 (02) :207-210

← 1 2 3 4 5 6 7 8 9 10 →